SCHEMBL9109399

SCHEMBL9109399

Cc1nc(COc2cc(C)n(-c3ccnc(-c4ccnc(C(C)(C)C)n4)c3)c(=O)c2C)cs1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 3/20 0.43
MAPKAPK5 Q8IW41 1/20 0.38
NMT1 P30419 1/20 0.33
MAPK14 Q16539 2/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
SLC6A4 P31645 1/20 0.33
HTR2B P41595 1/20 0.33
KDM4A O75164 1/20 0.32
KDM4B O94953 1/20 0.32
KDM5C P41229 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
CHEK1 O14757 2/20 0.31
F2RL3 Q96RI0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9110848 0.93 MAPKAPK2 (0.45) MAPKAPK2MAPKAPK5NMT1MAPK14HTR2A
SCHEMBL9108983 0.92 MAPKAPK2 (0.52) MAPKAPK2MAPKAPK5NMT1MAPK14HTR2A
SCHEMBL9110011 0.91 MAPK14 (0.43) MAPKAPK2MAPKAPK5MAPK14
SCHEMBL9110084 0.91 MAPKAPK2 (0.40) MAPKAPK2MAPKAPK5NMT1MAPK14HTR2A
SCHEMBL9112852 0.87 MAPKAPK2 (0.58) MAPKAPK2MAPKAPK5NMT1MAPK14HTR2A
SCHEMBL9111701 0.86 MAPKAPK2 (0.43) MAPKAPK2MAPKAPK5MAPK14
SCHEMBL9111410 0.86 NMT1 (0.33) MAPKAPK2MAPKAPK5NMT1MAPK14HTR2A
SCHEMBL9109604 0.86 MAPKAPK2 (0.53) MAPKAPK2MAPKAPK5NMT1MAPK14HTR2A
SCHEMBL9110410 0.85 MAPKAPK5 (0.54) MAPKAPK2MAPKAPK5NMT1MAPK14HTR2A
SCHEMBL9110525 0.85 MAPKAPK5 (0.42) MAPKAPK2MAPKAPK5NMT1MAPK14HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2648516-B1 SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS ACLARIS THERAPEUTICS INC (US) 2018-09-05 EP claimed
US-9365547-B2 Substituted pyridinone-pyridinyl compounds CONFLUENCE LIFE SCIENCES INC. (US) 2016-06-14 US claimed
US-20140171450-A1 SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES INC. (US) 2014-06-19 US claimed
US-20120142709-A1 SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS ACLARIS THERAPEUTICS, INC. 2012-06-07 US claimed
EP-3469907-B1 SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS ACLARIS THERAPEUTICS INC (US) 2021-03-03 EP disclosed
EP-3469907-A1 SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS Aclaris Therapeutics, Inc. (US) 2019-04-17 EP disclosed
EP-2648516-B1 SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS ACLARIS THERAPEUTICS INC (US) 2018-09-05 EP disclosed
US-9365547-B2 Substituted pyridinone-pyridinyl compounds CONFLUENCE LIFE SCIENCES INC. (US) 2016-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171450-A1 SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS MAPK1, MAP3K1, MAP3K6 MAPKAPK2 33/4885MAPKAPK5 35/4885NMT1 4164/4885
US-20120142709-A1 SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS MAPK1, MAP3K1, MAP3K6 MAPKAPK2 33/4885MAPKAPK5 35/4885NMT1 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.